Alkermes plc ( ALKS) - Key Metrics
ALKS Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $2.98 | $0 | $0.87 | $0.82 |
| 2026Q1 | $2.36 | -$0.40 | -$1 | -$1.02 |
| 2025Q4 | $2.33 | $0.30 | $1.03 | $1.03 |
| 2025Q3 | $2.39 | $0.50 | $0.62 | $0.51 |
| 2025Q2 | $2.37 | $0.53 | $0.91 | $0.83 |
ALKS Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | 4366.67 |
| 2026Q1 | 0% | -22.10 |
| 2025Q4 | 0% | 23.32 |
| 2025Q3 | 0% | 15 |
| 2025Q2 | 0% | 13.50 |
ALKS Free Cash Flow Yield and Dividend Yield
| Date | Free Cash Flow Yield | Dividend Yield |
|---|---|---|
| 2026Q2 | 1.57% | 0% |
| 2026Q1 | -2.89% | 0% |
| 2025Q4 | 3.69% | 0% |
| 2025Q3 | 1.70% | 0% |
| 2025Q2 | 2.91% | 0% |
ALKS
Price: $46.10
52 week price:
Payout Ratio Range:
Earnings Per Share: 0.38 USD
P/E Ratio: 130.34
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: Ireland
Volume: 283127
Ebitda: 39.2 millionMarket Capitalization: 8.3 billion